6 investors discuss why AI is more than just a buzzword in biotech
TechCrunch
DECEMBER 15, 2022
“Most of the companies we have seen have an AI component to support the discovery or development processes,” Francisco Dopazo, a general partner at Humboldt Fund told TechCrunch recently. We also see AI being used in the biologics space, although the technology is used there far earlier. We are many more above this.
Let's personalize your content